Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

3.03
-0.0100-0.33%
Post-market: 3.080.0500+1.65%19:51 EST
Volume:2.58M
Turnover:7.79M
Market Cap:906.99M
PE:-5.25
High:3.11
Open:3.02
Low:2.97
Close:3.04
52wk High:6.52
52wk Low:1.89
Shares:299.34M
Float Shares:202.75M
Volume Ratio:0.92
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5768
EPS(LYR):-0.5533
ROE:-16.81%
ROA:-10.43%
PB:0.94
PE(LYR):-5.48

Loading ...

Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares

Reuters
·
Nov 27, 2025

Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress

Simply Wall St.
·
Nov 26, 2025

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

TIPRANKS
·
Nov 20, 2025

Prelude Therapeutics reports third quarter net loss of $19.7 million

Reuters
·
Nov 12, 2025

Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call

Stock Track
·
Nov 11, 2025

AbCellera Biologics’ Earnings Call: Key Insights

TIPRANKS
·
Nov 11, 2025

Stock Track | AbCellera Biologics Soars 7.03% on Board Appointment and Clinical Progress

Stock Track
·
Nov 11, 2025

AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns

Reuters
·
Nov 10, 2025

Abcellera Appoints DR. Stephen Quake to Its Board of Directors

THOMSON REUTERS
·
Nov 10, 2025

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Potential Undervaluation

Stock Track
·
Nov 10, 2025

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Undervaluation

Stock Track
·
Nov 10, 2025

AbCellera Biologics (NasdaqGS:ABCL): How Does the Latest Clinical Progress Impact Its Valuation?

Simply Wall St.
·
Nov 10, 2025

Stock Track | AbCellera Biologics Plummets 20.31% on Wider Q3 Loss and Analyst Downgrade

Stock Track
·
Nov 07, 2025

Abcellera Biologics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $4 From $5

THOMSON REUTERS
·
Nov 07, 2025

Leerink Downgrades AbCellera Biologics to Market Perform From Outperform, Adjusts Price Target to $4 From $5

MT Newswires Live
·
Nov 07, 2025

Stock Track | AbCellera Biologics Plunges 9% Pre-market After Wider-Than-Expected Q3 Loss

Stock Track
·
Nov 07, 2025

Stock Track | AbCellera Biologics Surges 5.74% After Q3 Revenue Smashes Estimates

Stock Track
·
Nov 07, 2025

AbCellera Biologics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07, 2025

AbCellera Biologics Q3 revenue smashes estimates

Reuters
·
Nov 07, 2025

BRIEF-AbCellera Q3 Revenue USD 9 Million Vs. IBES Estimate USD 5.91 Million

Reuters
·
Nov 07, 2025